small molecule

TIBSOVO

IVOSIDENIB

Loss of exclusivityJune 2039latest FDA-listed patent expiry

CompanySERVIER PHARMACEUTICALS LLC

Drug detail

Brand name	TIBSOVO
Active ingredient	IVOSIDENIB
Strength	250MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
10980788	June 2039	use U-3113
10653710	October 2036	use U-3387
9968595	March 2035	product
10799490	March 2035	product
10449184	March 2035	product
9474779	August 2033	substance, product
10717764	January 2033	use U-3215
9850277	January 2033	substance, product
11667673	January 2033	use U-3742
10610125	June 2030	use U-3385

Regulatory exclusivity

Code	Expires
ODE-447	October 2030
ODE-368	August 2028
I-924	October 2026
ODE-242	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from SERVIER PHARMACEUTICALS LLC